CompletedNot Applicable

In Vitro Immunomodulation in Membranous Nephropathy Relapses

France20 participantsStarted 2022-05-23

Plain-language summary

In order to propose the best therapeutic option to relapsed MN patients with strong activation of the Th17 pathway, the investigators propose to study in vitro the effect of different immunomodulators on the Th17/Treg balance, assessed by cytokine profile and lymphocyte phenotyping using flow cytometry.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥ 18 years
✓. Patient with MN proven on renal biopsy or by the presence of anti-PLA2R1 or anti-THDS71 antibodies
✓. Relapsed MN, defined as proteinuria \> 3.5g/g after achieving remission (partial or complete, definitions according to KDIGO 2012 guidelines)
✓. At a distance from any immunosuppressive treatment (at least 6 months)
✓. Freely given informed consent signed by the patient after clear, fair and appropriate information
✓. Affiliated to a social security system

Exclusion criteria

✕. Pregnant or breastfeeding woman
✕. Patient under 18 years of age
✕. Persons of legal age

What they're measuring

Cytokine ELISA profiles of the Th17 pathway (IL-17 level), the Treg pathway (IL-10 level), the Th1 pathway (IL-12p70, IFN-γ) and the Th2 pathway (IL-4 and IL-5)

Timeframe: 18 months

Trial details

NCT IDNCT05428605

SponsorCentre Hospitalier Universitaire de Nice

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-05-30

View on ClinicalTrials.gov More Extramembranous Glomerulopathy trials